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Available online 4 May 2016Brexpiprazole, a serotonin-dopamine activity modulator, is a partial agonist at 5-HT1A and dopamine D2 recep-
tors, and antagonist at 5-HT2A and noradrenaline α1B and α2C receptors, all at similar potency. Efﬁcacy of
brexpiprazole was evaluated in patients with acutely exacerbated schizophrenia in three short-term, random-
ized, double-blind, placebo-controlled studies.
In a Phase 2 study, patients were randomized to brexpiprazole 0.25 mg (ﬁxed dose), 1.0 ± 0.5mg, 2.5 ± 0.5 mg,
5.0 ± 1mg (ﬂexible-dose ranges), placebo, or aripiprazole 15± 5mg. In two Phase 3 studies, patients were ran-
domized to ﬁxed-dose brexpiprazole 0.25 mg, 1 mg, 2 mg, or 4 mg, or placebo. For this review, brexpiprazole
2 mg and 4 mg arms from the Phase 3 studies were combined. Primary efﬁcacy endpoint was change in Positive
and Negative Syndrome Scale (PANSS) total score from baseline at week 6; key secondary endpoint was change
in Clinical Global Impression-Severity of illness (CGI-S) score at week 6. Primary outcome moderator analyses
explored effects of sex, age, race, and illness duration.
There were no statistically signiﬁcant differences vs. placebo in the Phase 2 brexpiprazole and aripiprazole
groups for primary and key secondary endpoints. Combined brexpiprazole 2 mg (n= 359) and 4 mg (n= 359)
were superior to placebo (n= 358) in change in PANSS total score (least square mean difference from placebo:
−5.46, p= 0.0004, and−6.69, p b 0.0001, respectively) and CGI-S (−0.25, p=0.0035, and−0.38, p b 0.0001,
respectively). Changes from baseline in efﬁcacy endpoints were minimal in the 0.25 mg group, while the 1 mg
group exhibited suboptimal improvement. No relevant moderators were identiﬁed.
Meta-analysis of the pivotal studies indicates brexpiprazole 2 mg and 4 mg are effective in treating acute
schizophrenia.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Schizophrenia1. Introduction
Treating patients with schizophrenia is complicated by difﬁcult-to-
predict responses to medication arising from variations between pa-
tients (Carbon and Correll, 2014; Correll et al., 2011). It has long been
recognized that individual patients respond heterogeneously (in terms
of both efﬁcacy and tolerability) to second-generation antipsychotics
(SGAs) (Citrome, 2013). In fact, meta-analyses and systematic reviewsital, Department of Psychiatry
ksandar.Skuban@otsuka-us.com
n.Ouyang@otsuka-us.com
Weiss@otsuka-us.com
. This is an open access article underof randomized controlled studies have identiﬁed comparatively small
variation in efﬁcacy among SGAs (Leucht et al., 2013a), but larger and
more predictable differences in tolerability and safety proﬁles
(Citrome, 2013; De Hert et al., 2011; Leucht et al., 2013a).
Choosing a treatment for a patient with schizophrenia is a complex
decision based on many factors, including symptom type and severity,
comorbidities, and previous treatment history (Correll, 2010). However,
few clinically useful predictors of treatment outcome have been identi-
ﬁed (Carbon and Correll, 2014), and limited guidance exists on how to
personalize the treatment decision. Factors that can be considered in-
clude the duration of untreated illness, non-adherence to antipsy-
chotics, and lack of an early response to treatment (Carbon and
Correll, 2014; Samara et al., 2015). Pooled or meta-analyses of data
from across several studies provide adequate power to conduct clini-
cally meaningful moderator and subgroup analyses that have thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ment option to those subgroups of patients with the highest potential
to beneﬁt (Correll et al., 2011).
The serotonin-dopamine activity modulator brexpiprazole, which
was approved in theUSA in July 2015 for the treatment of schizophrenia
and as an adjunctive therapy to antidepressants for the treatment of
major depressive disorder, acts both as a partial agonist at serotonin
5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin
5-HT2A and noradrenaline α1B and α2C receptors, all with similar po-
tency (Maeda et al., 2014). The intrinsic activity of brexpiprazole at D2
receptors is lower than that of the ﬁrst commercially available D2 partial
agonist, aripiprazole. Brexpiprazole's activity at D2 receptors may trans-
late into a reduced potential to induce adverse events (AEs) mediated
by agonism at the D2 receptor (e.g. akathisia, insomnia, restlessness,
and nausea) and D2 antagonist-like AEs (e.g. extrapyramidal symptoms
[EPS], hyperprolactinemia, and tardive dyskinesia) compared with
aripiprazole and full D2 antagonists, respectively (Fleischhacker, 2005;
Maeda et al., 2014). The efﬁcacy and safety of brexpiprazole for the
treatment of patients with an acute exacerbation of schizophrenia was
conﬁrmed in a Phase 3 program (Correll et al., 2015; Kane et al., 2015).
This overview summarizes efﬁcacy data from three short-term,mul-
ticenter, randomized, double-blind, placebo-controlled studies (one
Phase 2 and two Phase 3) that evaluated the efﬁcacy, safety, and tolera-
bility of brexpiprazole in patients with an acute exacerbation of schizo-
phrenia. Individual efﬁcacy data from the Phase 3 studies were reported
previously (Correll et al., 2015; Kane et al., 2015). Safety and tolerability
data for the Phase 2 study and the combined Phase 3 studies are shown
in the supplementarymaterial. Pooled safety and tolerability data across
the three short-term, placebo-controlled studies are reported separately
(Kane et al., 2016-in this issue).
2. Methods
2.1. Patients
All three studies recruited male and female patients aged
18–65 years with a current Diagnostic and Statistical Manual of Mental
Disorders, fourth edition, Text Revision (DSM-IV-TR) diagnosis of
schizophrenia who would beneﬁt from hospitalization or continued
hospitalization for treatment of an acute exacerbation. Exacerbation in
the Phase 2 studywas conﬁrmed at screening and baseline by a Positive
and Negative Syndrome Scale (PANSS; (Kay et al., 1987) total score ≥ 80
together with a Clinical Global Impression-Severity of illness (CGI-S;
(Guy, 1976) score ≥ 4. Patients in the Phase 3 studies had to have a
total Brief Psychiatric Rating Scale score ≥ 40 and a score of ≥ 4 on 2 or
more of the following BPRS items: hallucinatory behavior, unusual
thought content, conceptual disorganization, or suspiciousness, as well
as a CGI-S score ≥ 4 (at screening and baseline). Key exclusion criteria
were ﬁrst episode of schizophrenia, DSM-IV-TR Axis I diagnosis other
than schizophrenia, substance abuse or dependence in the previous
180 days, or a clinically signiﬁcant medical condition.
2.2. Study design
The Phase 2 study (NCT00905307, STEP 203)was amulticenter, ran-
domized, double-blind, six-arm, placebo- and active-controlled,
ﬂexible-dose study (Fig. 1A). Patients were randomized (1:2:2:2:2:1)
to receive double-blind brexpiprazole at a ﬁxed dose of 0.25mg or ﬂex-
ible doses of 1 ± 0.5 mg, 2.5 ± 0.5 mg, or 5 ± 1 mg, placebo, or
aripiprazole 15 ± 5 mg for 6 weeks. Aripiprazole was included to eval-
uate assay sensitivity. All patients received the target dose at baseline
without titration. Non-responders (Clinical Global Impressions-
Improvement (CGI-I; (Guy, 1976) score N 4 [“no change” or “worse”]
at weeks 3 and 4) were offered to switch to open-label brexpiprazole
but data collected during open-label treatment were not included in
the efﬁcacy analyses.The two Phase 3 studies had similar designs: bothweremulticenter,
randomized, double-blind, placebo-controlled, ﬁxed-dose trials (study
1, NCT01396421, VECTOR; study 2, NCT01393613, BEACON; Fig. 1B).
Methods have been described previously (Correll et al., 2015; Kane
et al., 2015). In study 1 patients were randomized to brexpiprazole
0.25 mg, 2 mg or 4 mg or placebo (1:2:2:2) and in study 2 patients
were randomized to brexpiprazole 1 mg, 2 mg or 4 mg or placebo
(2:3:3:3). The low brexpiprazole dose groups (0.25 and 1 mg) were in-
cluded to evaluate the lower dose range, based on results from Phase 2
studies that had indicated that 1 mgmay be the lowest efﬁcacious dose
of brexpiprazole; 0.25 mg was not expected to demonstrate efﬁcacy
(Thase et al., 2011). The 0.25 mg and 1 mg groups received that dose
from day 1 and throughout the study. The 2 mg and 4 mg groups
were titrated from 1 mg/day to 2 mg/day on day 5 and then, as appro-
priate, to 4 mg/day on day 8.
In all three studies, blocks of randomization numbers based on a pre-
generated permuted-block randomization schedule were assigned to
each study center using an interactive voice or web response system.
Eligible patients were sequentially assigned a randomization number
corresponding to one of the treatment groups. Blinding was assured
by restricting access of sponsor personnel to the treatment code and
providing identical tablets and packaging for brexpiprazole and placebo.
In the Phase 2 study, a double dummy technique was used since
aripiprazole differed in appearance from the brexpiprazole and placebo
tablets.
In the Phase 2 study, stable patients could, at the discretion of the in-
vestigator, be treated as outpatients afterweek 3. In the Phase 3 studies,
patients were hospitalized throughout the double-blind treatment
period.
All studies were conducted in compliance with the International
Conference on Harmonization Good Clinical Practice Consolidated
Guideline. Protocols were approved by independent ethics committees.
After complete description of the study to the patients, written in-
formed consent was obtained.
2.3. Efﬁcacy assessments
In all studies, efﬁcacy was assessed using the PANSS, CGI-S, CGI-I,
and Personal and Social Performance (PSP) scales (Morosini et al.,
2000). The primary efﬁcacy endpoint was change from baseline at
week 6 in PANSS total score. Secondary efﬁcacy endpoints for all studies
were change from baseline at week 6 in CGI-S (key secondary end-
point); change from baseline at weeks 1–5 in PANSS total score and
CGI-S; and change frombaseline atweek 6 in PSP scale score and in pos-
itive and negative symptom PANSS subscale scores; CGI-I at week 6;
responder rates (deﬁned as change from baseline in PANSS total
score ≥ 30% or CGI-I score of 1–2 at week 6); and discontinuation rate
due to lack of efﬁcacy. Additional secondary endpoints for the Phase 3
studies only were change from baseline at week 6 in PANSS Excited
Component score (Montoya et al., 2011) and in the ﬁve PANSS Marder
factor scores (Marder et al., 1997).
2.4. Safety assessments
The safety population comprised all patients who received at least
one dose of studymedication. Incidence of treatment-emergent adverse
events (TEAEs) andmean change from baseline to the last study visit in
EPS rating scales, weight, prolactin, and fasting metabolic parameters
were combined for the two Phase 3 studies.
2.5. Statistical analysis
The efﬁcacy population comprised all patients who received at least
one dose of study medication and had both a baseline assessment and
≥1 post-randomization efﬁcacy assessment during the double-blind
treatment period. Data from the Phase 2 study are reported separately.
Fig. 1. Study design for the Phase 2 study (A) and the Phase 3 studies (B). aTitration to assigned dose from baseline to the week 1 visit for patients randomized to brexpiprazole 2 mg or
4mg. Days 1–4: 1mg/day; days 5–7: 2mg/day; day 8: 4mg/day (in appropriate patients). B is adapted and reprinted from Schizophrenia Research 2015:164; 127–135. (Kane et al., 2015)
JohnM.Kane, Aleksandar Skuban, JohnOuyang,MaryHobart, Stephanie Pﬁster, Robert D.McQuade,MargarettaNyilas,WilliamH. Carson, Raymond Sanchez, Hans Eriksson. Amulticenter,
randomized, double-blind, controlled Phase 3 trial of ﬁxed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Copyright (2015), with permission from Elsevier.
Adapted and reprinted with permission from the American Journal of Psychiatry, (Copyright ©2015). American Psychiatric Association.
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combined. The two lower doses in the Phase 3 studies (0.25 mg and
1 mg) were not included in pre-speciﬁed primary analyses of Phase 3
studies and were excluded from the meta-analysis; their data are
reported separately.
The protocol-speciﬁed analysis for the primary endpoint (change
from baseline to week 6 in PANSS total score) in the Phase 2 study
was analysis of covariance (ANCOVA) based on the last observation
carried forward (LOCF) dataset. However, mixed model for repeated
measures (MMRM) analysis was applied as described for the Phase 3
studies below to facilitate comparison of data across studies. Forpatients who received open-label brexpiprazole, data from the last
visit prior to initiation of open-label treatment were carried forward
to week 6. The Hochberg procedure (Hochberg and Tamhane, 1987)
using a two-sided alpha of 0.05 was used to control the type I error
rate due to multiple comparisons.
For the combined Phase 3 data, the primary efﬁcacy endpoint,
change from baseline at week 6 in PANSS total score, was analyzed
using MMRM. The model included ﬁxed-effect factors of study, site
nested within study, treatment, visit, and treatment-by-visit interac-
tion, and ﬁxed-effect covariates of baseline score and baseline-by-visit
interaction. Least squares mean differences between brexpiprazole
85C.U. Correll et al. / Schizophrenia Research 174 (2016) 82–92and placebo derived from the MMRM analysis were tested statistically.
The key secondary efﬁcacy endpoint, change from baseline at week 6 in
CGI-S score, was analyzed using the same MMRM model. MMRM
analysis was also applied to changes from baseline in PSP scale score,
PANSS subscale scores, PANSS Excited Component score, and PANSS
Marder factor scores. CGI-I score at week 6 was analyzed using the
Cochran-Mantel-Haenszel (CMH) row mean scores test (Davis and
Chung, 1995), controlling for site; responder rate (mean change from
baseline in PANSS total score of ≥30% or CGI-I score of 1 or 2 [very
much improved or much improved] at week 6) and discontinuation
rates due to lack of efﬁcacy were analyzed by the CMH general associa-
tion test (Cochran, 1954).
Pre-planned treatment-by-subgroup interaction analyses by age
(b 55 years; ≥ 55 years), sex (male; female), and race (white; other
races) were performed using the MMRM for change from baseline at
week 6 in PANSS total score.
Post-hoc analyses included responder rates based on ≥ 20%, ≥ 40%,
and ≥50% reductions in PANSS total score or a CGI-I score of 1 or 2 at
week 6 (as deﬁned in the two Phase 3 studies (Correll et al., 2015;
Kane et al., 2015)) for combined brexpiprazole 2 mg, 4 mg, and placebo
groups;MMRManalysis of change from baseline atweek 6 in individual
PSP items: socially useful activities, personal and social relationships,
self-care, and disturbing and aggressive behaviors; regression analysis
derived from a model of mean change from baseline at week 6 in
PANSS total score with factors of disease duration and treatment; and
MMRM analysis of change from baseline at week 6 in PANSS total
score for duration of illness subgroups deﬁned by tertiles to ensure ad-
equate patient numbers in each subgroup. In addition, for the combined
Phase 3 data, Cohen's d-effect sizes for the primary and key secondary
efﬁcacy endpoints were calculated as treatment-placebo difference
divided by pooled standard deviation with 95% conﬁdence intervals
derived using the delta method. Number-needed-to-treat (NNT) forFig. 2. Patient disposition for the Phase 2 study (A) and the Phase 3 studies (B) (randomized
combined from studies 1 and 2. AE, adverse events; OL, open-label brexpiprazole.responder rates was calculated as 100 divided by the absolute risk
reduction.
3. Results
3.1. Patients
Overall, 268/459 (58.4%) patients completed the Phase 2 study, with
a greater proportion of completers in the 1 ± 0.5 mg, 2.5 ± 0.5 mg, or
5 ± 1mg brexpiprazole and aripiprazole groups than placebo (Fig. 2A).
Patients included in the meta-analysis were randomized to
brexpiprazole 2 mg (n = 368), 4 mg (n = 364), or placebo (n = 368)
[Fig. 2B]. More patients completed the study in the combined
brexpiprazole groups thanwith placebo (2mg: 68.8%; 4mg: 69.0%; pla-
cebo: 61.7%). The efﬁcacy population included 359, 359, and 358 pa-
tients in the combined brexpiprazole 2 mg, 4 mg, and placebo groups,
respectively. Patient disposition for the brexpiprazole 0.25 mg and
1 mg groups is shown in Fig. 2B.
Demographic and baseline clinical characteristics were similar
across all treatment groups (Tables 1A and 1B).
3.2. Positive and negative syndrome scale total score (primary efﬁcacy
endpoint)
In the Phase 2 study, none of the active groups (brexpiprazole or
aripiprazole) were signiﬁcantly different from placebo for change
from baseline in PANSS total score at week 6 (Table 2A), although
changes from baseline in all active groups were similar and numerically
greater than placebo. Additionally, none of the active groups met the
primary efﬁcacy endpoint in the protocol-speciﬁed analysis (ANCOVA
on LOCF), as none of the brexpiprazole treatment groups achieved
p b 0.05 compared with placebo (p= 0.2263, p= 0.0949, p= 0.6066,population). aPlacebo, brexpiprazole 2 mg/day, and brexpiprazole 4 mg/day groups are
Table 1
Demographic and baseline clinical characteristics for the Phase 2 study (A) and the Phase 3 studies (B) (efﬁcacy population).
A. Phase 2 study Placebo
(n = 93)
Brexpiprazole Aripiprazole
15 ± 5 mg
(n = 50)
0.25 mg
(n = 41)
1 ± 0.5 mg
(n = 88)
2.5 ± 0.5 mg
(n = 90)
5 ± 1 mg
(n = 92)
Demographic characteristics
Age (years), mean (SD) 38.8 (11.5) 40.8 (9.0) 39.2 (10.3) 37.4 (10.0) 39.3 (11.0) 40.8 (11.0)
BMI (kg/m2), mean (SD) 26.4 (5.4) 26.8 (6.5) 27.1 (7.2) 25.9 (5.5) 25.3 (6.4) 24.7 (4.8)
Sex, n (%)
Female 37 (39.8) 14 (34.1) 35 (39.8) 30 (33.3) 37 (40.2) 16 (32.0)
Race, n (%)
Caucasian 58 (62.4) 26 (63.4) 50 (56.8) 56 (62.2) 59 (64.1) 34 (68.0)
Other 35 (37.6) 15 (36.6) 38 (43.2) 34 (37.8) 33 (35.9) 16 (32.0)
Clinical characteristics
Age at ﬁrst diagnosis (years), mean (SD) 25.6 (7.8) 27.2 (8.5) 26.5 (8.9) 25.9 (9.0) 26.7 (9.2) 26.8 (8.4)
Duration of current episode (weeks), mean (SD) 3.2 (2.8) 2.6 (2.1) 2.5 (1.6) 2.9 (2.4) 2.3 (1.6) 2.9 (2.7)
PANSS, mean (SD)
Total score 97.5 (9.9) 97.3 (8.5) 96.2 (10.0) 98.6 (10.5) 97.8 (11.0) 97.1 (10.7)
Positive subscale 25.6 (3.5) 25.3 (3.4) 25.0 (3.7) 25.4 (3.8) 25.5 (3.8) 25.9 (3.7)
Negative subscale 24.9 (4.5) 24.2 (4.4) 24.5 (4.1) 25.8 (4.6) 25.1 (5.0) 23.9 (4.2)
CGI-S score, mean (SD) 5 (0.6) 4.8 (0.6) 4.8 (0.6) 5 (0.6) 5 (0.6) 4.9 (0.7)
B. Phase 3 studiesa Placebob
(n = 358)
Brexpiprazole
0.25 mg
(n = 87)
1 mg
(n = 117)
2 mgb
(n = 359)
4 mgb
(n = 359)
Demographic characteristics
Age (years), mean (SD) 39.7 (10.8) 40.8 (11.4) 38.8 (11.9) 38.2 (10.6) 39.6 (11.1)
BMI (kg/m2), mean (SD) 26.5 (5.5) 26.3 (6.3) 26.7 (5.8) 26.7 (5.8) 27.1 (6.2)
Sex, n (%)
Female 135 (37.7) 28 (32.2) 42 (35.9) 132 (36.8) 138 (38.4)
Race, n (%)
Caucasian 226 (63.1) 62 (71.3) 73 (62.4) 233 (64.9) 218 (60.7)
Other 132 (36.9) 25 (28.7) 44 (37.6) 126 (35.1) 141 (39.3)
Clinical characteristics
Age at ﬁrst diagnosis (years), mean (SD) 26.7 (9.2) 27.6 (8.9) 26.1 (8.9) 25.9 (8.1) 26.8 (8.6)
Duration of current episode (weeks), mean (SD) 2.7 (2.8) 2.6 (1.9) 2.4 (2.8) 2.7 (2.7) 2.4 (1.9)
PANSS, mean (SD)
Total score 95.2 (12.2) 93.6 (11.5) 93.2 (12.7) 96.1 (13.3) 94.8 (12.2)
Positive subscale 25.1 (4.4) 25.0 (3.5) 25.0 (4.3) 25.2 (4.3) 24.9 (4.4)
Negative subscale 23.7 (4.9) 22.7 (4.5) 23.1 (5.4) 23.7 (5.0) 23.6 (4.8)
CGI-S score, mean (SD) 4.8 (0.6) 4.9 (0.6) 4.9 (0.7) 4.9 (0.6) 4.8 (0.6)
BPRS total score, mean (SD) 55.2 (7.8) 55.2 (7.5) 54.2 (8.6) 55.9 (8.1) 55.1 (7.4)
BMI, body mass index; BPRS, Brief Psychiatric Rating Scale; CGI-S, Clinical Global Impression – Severity of illness; PANSS, Positive and Negative Syndrome Scale; SD, standard deviation.
a Correll et al. (2015); Kane et al. (2015).
b Placebo, brexpiprazole 2 mg, and brexpiprazole 4 mg groups are combined from studies 1 and 2.
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1.0 mg treatment groups, respectively).
In the Phase 3 studies, while the 2mg armwas not statistically differ-
ent from placebo in study 2 (Kane et al., 2015), the combined 2 mg
and 4mg groups showed statistically signiﬁcantly greater improvements
from baseline at week 6 in PANSS total score compared with placebo
(p = 0.0004 and p b 0.0001, Cohen's d effect size 0.27 and 0.33,
respectively; Table 2B). In both groups, a signiﬁcant treatment
effect was apparent at week 1 and was maintained throughout the
treatment period (Fig. 3A). Changes from baseline at week 6 were
minimal in the 0.25 mg group, while the 1 mg brexpiprazole group
exhibited a suboptimal response that was less than that for either
2 mg or 4 mg (Table 2B).
3.3. Secondary efﬁcacy endpoints
In the Phase 2 study, numerically greater improvements from base-
line were seen in the ﬂexible-dose brexpiprazole and aripiprazole
groups compared with placebo for some of the secondary efﬁcacy end-
points (Table 2A).
In the Phase 3 studies, the combined brexpiprazole 2 mg and 4 mg
groups were different from placebo for the key secondary efﬁcacy end-
point, mean change from baseline at week 6 in CGI-S total score(Table 2B, Figs. 3B and 4). Brexpiprazole 2 mg and 4 mg consistently
showed greater improvement compared with placebo (p b 0.05) in all
other secondary endpoints, with the exception of discontinuation rate
due to lack of efﬁcacy in the combined 2 mg group (Table 2B). NNTs for
response ≥ 30% improvement to brexpiprazole 2 mg and 4 mg were 9
and 6, respectively. A post-hoc analysis showed improvements
(p b 0.05 vs. placebo) in all individual PSP scale items in the brexpiprazole
4mggroup, and improvements in socially useful activities and self-care in
the 2 mg group (Fig. 5).
Brexpiprazole 0.25 mg and 1 mg demonstrated less improvement
over placebo in the secondary efﬁcacy endpoints, consistent with the
primary endpoint (Table 2B).
3.4. Subgroup analyses
For the primary efﬁcacy endpoint, no treatment-by-subgroup inter-
actions were found for age or sex for any of the combined or individual
treatment groups. There was also no treatment-by-subgroup interac-
tion for race in the combined 2 mg group and all the Phase 2 study
groups. In the combined 4 mg group, the change from baseline at
week 6 in PANSS total score was smaller in Caucasian patients than in
those of other races (interaction by race, p=0.0328), but the difference
between brexpiprazole and placebowas statistically signiﬁcant for both
Table 2
Efﬁcacy endpoints for the Phase 2 study (A) and the Phase 3 studies (B) (efﬁcacy population).
A. Phase 2 study Placebo
(n = 93)
Brexpiprazole Aripiprazole
15 ± 5 mg
(n = 50)
0.25 mg
(n = 41)
1 ± 0.5 mg
(n = 88)
2.5 ± 0.5 mg
(n = 90)
5 ± 1 mg
(n = 92)
Primary efﬁcacy endpoint
PANSS total score, n 93 41 88 90 92 50
LS mean change (SE)a −17.28 (2.19) −12.41 (3.41) −21.98 (2.19) −19.00 (2.25) 21.73 (2.19) 20.97 (2.93)
Treatment difference (95% CI) – 4.88 (−3.09, 12.85) −4.69 (−10.8, 1.39) −1.72 (−7.89, 4.46) −4.45 (−10.5, 1.63) −3.68 (−10.9, 3.51)
p-value − 0.2288 0.1299 0.5841 0.1508 0.3142
Secondary efﬁcacy endpoints
CGI-S total score, n 93 41 88 90 92 50
LS mean change (SE)a −1.05 (0.12) −0.63 (0.19) −1.27 (0.12) −1.12 (0.13) −1.35 (0.12) −1.30 (0.16)
Treatment difference (95% CI) – 0.41 (−0.04, 0.87) −0.23 (−0.57, 0.11) −0.07 (-0.42, 0.28) −0.30 (−0.64, 0.04) −0.25 (−0.65, 0.15)
p-value – 0.0714 0.1900 0.6894 0.0813 0.2135
PSP scale score, n 90 39 86 84 90 50
LS mean change (SE)a 12.42 (1.38) 12.08 (2.22) 15.59 (1.38) 14.62 (1.42) 16.40 (1.37) 14.85 (1.83)
Treatment difference (95% CI) – −0.34 (−5.42, 4.75) 3.18 (−0.63, 6.98) 2.20 (−1.67, 6.07) 3.98 (0.20, 7.77) 2.43 (−2.06, 6.92)
p-value – 0.8966 0.1016 0.2638 0.0391 0.2873
PANSS positive subscale score, n 93 41 88 90 92 50
LS mean change (SE)a −5.70 (0.71) −4.11 (1.11) −7.06 (0.71) −6.20 (0.73) −6.99 (0.71) −7.58 (0.95)
Treatment difference (95% CI) – 1.59 (−1.01, 4.18) −1.36 (−3.33, 0.62) −0.49 (−2.50, 1.51) −1.28 (−3.26, 0.69) −1.88 (−4.21, 0.46)
p-value – 0.2296 0.1774 0.6283 0.2015 0.1154
PANSS negative subscale score 93 41 88 90 92 50
LS mean change (SE)a −4.03 (0.51) −3.02 (0.80) −4.70 (0.51) −4.59 (0.52) −4.92 (0.51) −4.37 (0.68)
Treatment difference (95% CI) – 1.01 (−0.86, 2.87) −0.67 (−2.08, 0.74) −0.56 (−1.99, 0.88) −0.89 (−2.30, 0.52) −0.34 (−2.01, 1.33)
p-value – 0.2887 0.3526 0.4436 0.2129 0.6905
CGI-I score, n 93 41 88 90 92 50
Mean at week 6 (SD) 3.34 (1.54) 3.66 (1.48) 3.08 (1.58) 3.17 (1.45) 3.04 (1.50) 3.04 (1.52)
Treatment difference (95% CI) – 0.20 (−0.41, 0.81) −0.35 (−0.81, 0.11) −0.15 (−0.56, 0.26) −0.30 (−0.72, 0.12) −0.35 (−0.90, 0.20)
p-valueb – 0.5218 0.1399 0.4620 0.1653 0.2083
Responder ratec, n 93 41 88 90 92 50
Rate (%) 50.5 41.5 58.0 46.7 52.2 60.0
Relative risk (95% CI) – 0.90 (0.58, 1.41) 1.19 (0.96, 1.48) 0.89 (0.64, 1.22) 1.01 (0.78, 1.33) 1.13 (0.83, 1.53)
p-valued – 0.6520 0.1492 0.4430 0.9165 0.4677
NNT – NAe 14 NAe 50 11
Discontinuation due to lack of efﬁcacy, n 93 41 88 90 92 50
Rate (%) 8.6 14.6 4.5 5.6 5.4 8.0
Relative risk (95% CI) – 1.36 (0.50, 3.72) 0.51 (0.19, 1.40) 0.57 (0.20, 1.60) 0.64 (0.25, 1.66) 0.76 (0.21, 2.69)
p-valued – 0.5525 0.1957 0.2856 0.3668 0.6697
B. Phase 3 studiesf Placebog
(n = 358)
Brexpiprazole
0.25 mgh
(n = 87)
1 mgh
(n = 117)
2 mgg
(n = 359)
4 mgg
(n = 359)
Primary efﬁcacy endpoint
PANSS total score, n 358 87 117 359 359
LS mean change (SE)a −13.33 (1.10) −14.90 (2.23) −16.90 (1.86) −18.79 (1.07) −20.01 (1.07)
Treatment difference (95% CI) – −2.89 (−8.27, 2.49) −3.37 (−8.06, 1.32) −5.46 (−8.46,−2.47) −6.69 (−9.67,−3.70)
p-value – 0.2910 0.1588 0.0004 b0.0001
Cohen's d effect size (95% CI) – – – 0.27 (−0.03, 0.57) 0.33 (−0.03, 0.68)
Secondary efﬁcacy endpoints
CGI-S total score, n 362 89 120 361 361
LS mean change (SE)a −0.82 (0.06) −0.85 (0.12) −0.91 (0.11) −1.07 (0.06) −1.20 (0.06)
Treatment difference (95% CI) – −0.03 (−0.31, 0.26) −0.10 (−0.37, 0.16) −0.25 (−0.42,−0.08) −0.38 (−0.55,−0.22)
p-value − 0.8491 0.4449 0.0035 b0.0001
Cohen's d effect size (95% CI) − − − 0.21 (−0.04, 0.47) 0.34 (−0.02, 0.71)
PSP scale score, n 333 86 105 343 342
LS mean change (SE)a 9.51 (0.71) 11.84 (1.33) 11.73 (1.19) 11.99 (0.68) 13.01 (0.68)
Treatment difference (95% CI) – 1.58 (−1.58, 4.74) 3.21 (0.26, 6.16) 2.48 (0.63, 4.32) 3.50 (1.66, 5.33)
p-value – 0.3264 0.0332 0.0086 0.0002
Cohen's d effect size (95% CI) – – – 0.20 (−0.05, 0.45) 0.29 (−0.03, 0.61)
PANSS positive subscale score, n 358 87 117 359 359
LS mean change (SE)a –4.74 (0.37) −5.46 (0.74) −5.63 (0.62) −6.06 (0.36) −6.76 (0.36)
Treatment difference (95% CI) – −1.11 (−2.90, 0.68) −0.68 (−2.26, 0.89) −1.31 (−2.32,−0.31) −2.02 (−3.02,−1.02)
p-value – 0.2227 0.3938 0.0107 b0.0001
Cohen's d effect size (95% CI) – – – 0.19 (−0.05, 0.43) 0.30 (−0.03, 0.62)
PANSS negative subscale score, n 358 87 117 359 359
LS mean change (SE)a −2.31 (0.27) −3.31 (0.53) −2.92 (0.48) −3.51 (0.26) −3.59 (0.26)
Treatment difference (95% CI) – −1.07 (−2.33, 0.20) −0.78 (−1.98, 0.42) −1.20 (−1.93,−0.46) −1.28 (−2.01,−0.54)
p-value – 0.0996 0.2004 0.0015 0.0007
Cohen's d effect size (95% CI) – – – 0.24 (−0.04, 0.51) 0.25 (−0.04, 0.54)
PANSS Excited Component score, n 358 87 117 359 359
LS mean change (SE)a −1.95 (0.22) −1.99 (0.49) −1.94 (0.41) −2.64 (0.21) −3.06 (0.21)
Treatment difference (95% CI) – −0.34 (−1.53, 0.85) −0.48 (−1.51, 0.56) −0.69 (−1.28,−0.11) −1.11 (−1.70,−0.53)
(continued on next page)
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Table 2 (continued)
B. Phase 3 studiesf Placebog
(n = 358)
Brexpiprazole
0.25 mgh
(n = 87)
1 mgh
(n = 117)
2 mgg
(n = 359)
4 mgg
(n = 359)
p-value – 0.5706 0.3646 0.0200 0.0002
Cohen's d effect size (95% CI) – – – 0.17 (−0.05, 0.40) 0.28 (−0.03, 0.59)
CGI-I score, n 362 89 120 361 361
Mean at week 6 (SD) 3.48 (1.46) 3.37 (1.46) 3.20 (1.45) 3.06 (1.35) 2.94 (1.31)
Treatment difference (95% CI) – −0.14 (−0.50, 0.22) −0.24 (−0.56, 0.08) −0.42 (−0.62,−0.22) −0.50 (−0.71,−0.30)
p-valueb – 0.450 0.1358 b0.0001 b0.0001
Cohen's d effect size (95% CI) – – – 0.30 (−0.03, 0.63) 0.36 (−0.02, 0.74)
Responder ratesc
≥ 20% improvement, n 358 – – 359 359
Rate (%) 37.4 – – 48.5 53.8
Relative risk (95% CI) – – – 1.31 (1.11, 1.55) 1.42 (1.21, 1.66)
p-valued – – – 0.0015 b0.0001
NNT – – – 9 7
≥30% improvement, n 358 87 117 359 359
Rate (%) 31.0 39.1 43.6 43.2 47.9
Relative risk (95% CI) – 1.27 (0.92, 1.76) 1.35 (1.02, 1.79) 1.40 (1.16, 1.69) 1.51 (1.26, 1.81)
p-valued – 0.1576 0.0433 0.0005 b0.0001
NNT – 12 9 9 6
≥40% improvement, n 358 – – 359 359
Rate (%) 30.4 – – 41.8 46.5
Relative risk (95% CI) – – – 1.38 (1.14, 1.67) 1.50 (1.25, 1.81)
p-valued – – – 0.0009 b0.0001
NNT – – – 9 7
≥50% improvement, n 358 – – 359 359
Rate (%) 29.9 – – 41.8 46.2
Relative risk (95% CI) – – – 1.41 (1.16, 1.71) 1.52 (1.26, 1.83)
p-valued – – – 0.0005 b0.0001
NNT – – – 9 7
Discontinuation due to lack of efﬁcacy, n 358 87 117 359 359
Rate (%) 10.9 8.0 7.7 10.3 6.4
Relative risk (95% CI) – 0.77 (0.35, 1.68) 0.76 (0.36, 1.59) 0.94 (0.60, 1.46) 0.61 (0.38, 0.98)
p-valued – 0.5115 0.4586 0.7796 0.0395
PANSS factor scores as deﬁned by Marder et al.i
Positive symptoms, n 358 87 117 359 359
LS mean change (SE)a −5.95 (0.33) −5.78 (0.73) −6.56 (0.66) −7.17 (0.32) −7.55 (0.32)
Treatment difference (95% CI) – −0.89 (−2.66, 0.89) −0.65 (−2.32, 1.01) −1.22 (−2.11,−0.33) −1.61 (−2.49,−0.72)
p-value – 0.3263 0.4423 0.0070 0.0004
Cohen's d effect size (95% CI) – – – 0.20 (−0.04, 0.45) 0.27 (−0.03, 0.56)
Negative symptoms, n 358 87 117 359 359
LS mean change (SE)a −2.82 (0.28) −3.66 (0.54) −3.55 (0.48) −4.06 (0.27) −4.06 (0.27)
Treatment difference (95% CI) – −0.86 (−2.17, 0.44) −1.00 (−2.22, 0.22) −1.24 (−1.99,−0.48) −1.24 (−1.99,−0.49)
p-value – 0.1956 0.1080 0.0013 0.0012
Cohen's d effect size (95% CI) – – – 0.24 (−0.04, 0.52) 0.24 (−0.04, 0.52)
Disorganized thought, n 358 87 117 359 359
LS mean change (SE)a −2.36 (0.26) −2.69 (0.52) −3.46 (0.43) −3.48 (0.25) −3.89 (0.25)
Treatment difference (95% CI) – −0.72 (−1.96, 0.52) −0.87 (−1.96, 0.21) −1.12 (−1.83,−0.42) −1.54 (−2.24,−0.83)
p-value – 0.2572 0.1150 0.0018 b0.0001
Cohen's d effect size (95% CI) – – – 0.23 (−0.04, 0.51) 0.32 (−0.03, 0.66)
Uncontrolled hostility/excitement, n 358 87 117 359 359
LS mean change (SE)a −0.79 (0.21) −1.15 (0.41) −0.90 (0.36) −1.41 (0.20) −1.97 (0.20)
Treatment difference (95% CI) – −0.33 (−1.31, 0.66) −0.26 (−1.16, 0.65) −0.62 (−1.18,−0.06) −1.18 (−1.75,−0.62)
p-value – 0.5172 0.5752 0.0311 b0.0001
Cohen's d effect size (95% CI) – – – 0.16 (−0.05, 0.38) 0.31 (−0.03, 0.64)
Anxiety/depression, n 358 87 117 359 359
LS mean change (SE)a −3.04 (0.18) −3.27 (0.35) −3.57 (0.30) −3.72 (0.17) −3.65 (0.17)
Treatment difference (95% CI) – −0.21 (−1.07, 0.64) −0.64 (−1.39, 0.10) −0.69 (−1.17,−0.21) −0.61 (−1.09,−0.13)
p-value – 0.6251 0.0890 0.0053 0.0126
Cohen's d effect size (95% CI) – – – 0.21 (−0.04, 0.46) 0.19 (−0.05, 0.42)
Bold text indicates p b 0.05 comparedwith placebo. For the Phase 3 studies, combined brexpiprazole 2mg and 4mg groups are comparedwith the combined placebo group. Brexpiprazole
0.25 mg and 1 mg groups are compared with the placebo groups from the individual studies.
CGI-I, Clinical Global Impressions– Improvement; CGI-S, Clinical Global Impressions– Severity of illness; CI, conﬁdence interval; CMH, Cochran-Mantel-Haenszel; LS, least squares; NA, not
available; NNT, number needed-to-treat; PANSS, Positive and Negative Syndrome Scale; PSP scale, Personal and Social Performance scale; SE, standard error.
a LS mean (SE) change from baseline at week 6; p-value (brexpiprazole vs. placebo) is derived from a mixed-model repeated measures analysis.
b p-value (brexpiprazole vs. placebo) derived from CMH row mean scores differ test.
c Deﬁned as mean change from baseline in PANSS total score ≥ 30% (protocol-deﬁned) or ≥20%, ≥40%, or ≥50% (post hoc) or CGI-I score of 1 (very much improved) or 2 (much
improved) at week 6.
d p-value (brexpiprazole vs. placebo) derived from CMH general association test.
e NNT could not be calculated as the responder rate was higher in the placebo group than the brexpiprazole group.
f Correll et al. (2015); Kane et al. (2015).
g Placebo, brexpiprazole 2 mg, and 4 mg groups were combined from studies 1 and 2.
h Statistical analysis was exploratory for all parameters; treatment differences and p-values were obtained from the individual studies.
i Marder et al. (1997).
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p b 0.0001).3.5. Post-hoc analyses by duration of illness
Regression analysis showed aweak, but statistically signiﬁcant, neg-
ative association between reduction in PANSS total score and duration
of illness (r = 0.18, p= 0.0049). Grouping illness duration in tertiles,
in the combined 2 mg brexpiprazole group, the response was greater
in patients with shorter duration of illness. In contrast, consistent efﬁ-
cacy was seen across all tertiles in the combined 4 mg group (Table 3).3.6. Safety and tolerability
Safety data for the Phase 2 study and the combined Phase 3 studies
are shown in the supplementary material, including the incidence of
TEAEs (Table S1) and the mean change from baseline to the last study
visit in EPS rating scales (Table S2), weight, prolactin, and fastingmeta-
bolic parameters (Table S3).Fig. 3. Least squaresmean (standard error) change from baseline in Positive and Negative Synd
combined brexpiprazole 2 mg and 4 mg and placebo groups (efﬁcacy population). *p b 0.05, **
groups are compared with the combined placebo group. BREX, brexpiprazole; CGI-S, Clinical G
standard error.4. Discussion
The short-term efﬁcacy of brexpiprazole for the treatment of pa-
tients with an acute exacerbation of schizophrenia was evaluated in
one Phase 2 and two similarly designed Phase 3 studies. The Phase 2
study did not meet its primary efﬁcacy endpoint because change from
baseline at week 6 in PANSS total score did not differ signiﬁcantly
from placebo in any of the brexpiprazole groups. However, the active
control aripiprazole group did not separate fromplacebo either, indicat-
ing a lack of adequate assay sensitivity. It is likely that this study failed
because of the relatively high placebo response (which is not unusual
in studies with multiple active treatment arms, especially in more re-
cently conducted studies (Agid et al., 2013), which may have obscured
true treatment-related beneﬁts. However, numerical improvements in
psychiatric scale scores at week 6 were observed in all ﬂexible-dose
brexpiprazole groups vs. placebo, suggesting that dosages of
brexpiprazole between 1 mg/day and 5 mg/day may be effective in
this population. Since data indicated that the incidence of akathisia in-
creased at doses above 4 mg (Kane et al., 2016-in this issue), the 5 mg
dose was not used in the Phase 3 trials. However, one needs to consider
that, in the Phase 2 study, the 5 mg dose was started without anyrome Scale total score (A) and Clinical Global Impressions – Severity of illness score (B) for
p b 0.01, ***p b 0.001; mixed-model repeated measures analysis. Combined brexpiprazole
lobal Impressions – Severity of illness; PANSS, Positive and Negative Syndrome Scale; SE,
Fig. 4. Estimated treatment effects for change from baseline at week 6 in Clinical Global Impressions – Severity of illness score (efﬁcacy population). Combined brexpiprazole 2 mg and
4 mg groups are compared with the combined placebo group. Phase 2 brexpiprazole groups and Phase 3 brexpiprazole 0.25 mg and 1 mg groups are compared with the placebo
groups from the individual studies. ARIP, aripiprazole; BREX, brexpiprazole; LCL, lower conﬁdence limit; LSMD, least squares mean difference; UCL, upper conﬁdence limit.
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1 mg for 4 days, followed by 2 mg at day 5 and 4 mg at day 8 (Correll
et al., 2015; Kane et al., 2015). Whether brexpiprazole could be started
safely at 2 mg and whether doses higher than 4 mg could be well toler-
ated and effective in patients receiving suboptimal beneﬁts from 4 mg
should be determined in future studies.
Meta-analysis of two Phase 3 studies demonstrated that
brexpiprazole 2 mg and 4 mg were effective in adults with an acute ex-
acerbation of schizophrenia, as evidenced by superiority over placebo in
both the primary efﬁcacy endpoint, change in PANSS total score, and the
key secondary efﬁcacy endpoint, change in CGI-S. Brexpiprazole 2 mg
and 4 mg also showed signiﬁcantly greater improvement compared
with placebo in most other secondary efﬁcacy endpoints, including
PSP scale, positive and negative PANSS subscales, PANSS Excited Com-
ponent score, responder rates, and PANSS factor scores as deﬁned by
Marder et al. (Marder et al., 1997). Althoughmany elements contribute
to disability in schizophrenia, it is known that expression of prominent
symptoms is associated with functional impairment (Rabinowitz et al.,
2013).
Brexpiprazole had a positive effect on social and personal functioning
in the PSP scale domains of socially useful activities, relationships, self-
care, and disturbing and aggressive behavior, perhaps reﬂecting its abilityFig. 5. Least squares mean (standard error) change from baseline at week 6 in individual
Personal and Social Performance scale items for combined brexpiprazole 2 mg and 4 mg
and placebo groups (efﬁcacy population). p b 0.05, **p b 0.01, ***p b 0.001; mixed-
model repeated measures analysis. Combined brexpiprazole 2 mg and 4 mg groups are
compared with the combined placebo group. BREX, brexpiprazole; SE, standard error.to reduce symptoms. Subgroup analyses indicated that brexpiprazole had
a consistent effect on PANSS total score across male and female patients,
older and younger patients (≥ 55 vs. b 55 years), and different races (Cau-
casian vs. other races), suggesting that these symptom-related beneﬁts
are not limited to speciﬁc patient subgroups. Treatment effects were
also seen in patients with early and late stages of illness.
Despite the availability of a range of SGAs with various mechanisms
of action, schizophrenia remains a difﬁcult condition to treat.
Brexpiprazole has a high afﬁnity for 5-HT1A and 5-HT2A receptors that
is similar to its afﬁnity at D2 receptors and higher than that of
aripiprazole (Maeda et al., 2014). This balanced binding proﬁle may
provide additional clinical beneﬁts, because 5-HT2A antagonism is
thought to contribute to antipsychotic activity (Ebdrup et al., 2011),
and contribute to a balanced safety proﬁle, because 5-HT2A antagonism
is thought to counter EPS and akathisia (Kane et al., 2016-in this issue;
(Laoutidis and Luckhaus, 2014). Brexpiprazole also has a moderately
low relative afﬁnity for receptors (e.g. H1 histamine receptors) that
have been associated with sedation (Maeda et al., 2014). The safety
data from the pooled Phase 3 studies indicate that brexpiprazole is
well tolerated with a low incidence of EPS-related TEAEs and akathisia
as well as a low incidence of sedation and somnolence, reﬂecting its
pharmacological proﬁle.
In the pivotal 4- to 6-week, double-blind, placebo-controlled clinical
trials in patients with acute exacerbations of schizophrenia, aripiprazole
10–30 mg/day signiﬁcantly reduced mean PANSS score from baseline
by 11 to 16 points, comparedwith a reduction of 2 to 5 points in the pla-
cebo groups (Cutler et al., 2006; Kane et al., 2002; McEvoy et al., 2007;
Potkin et al., 2003). Although direct comparisons of studies with differ-
ent methodologies should be made with caution, the brexpiprazole-
placebo difference from the meta-analysis results reported here appear
to be in the same range as those of aripiprazole. However, it should be
noted that the improvement seen with placebo was more than double
that seen in the aripiprazole studies (mean PANSS total score reduction
of 12 points with placebo compared with 18 and 20 points with
brexpiprazole). An increasing placebo response over time has been ob-
served before (Agid et al., 2013; Alphs et al., 2012), having resulted in
smaller effect sizes in antipsychotics studied more recently (Correll
and De Hert, 2013). In addition, NNTs and effect sizes have been used
to provide an indirect comparison of different SGAs, although this ap-
proach is limited by differences between studies in the placebo re-
sponse (Huhn et al., 2014; Leucht et al., 2013b) and the deﬁnition of
response (Leucht, 2014). From the combined Phase 3 studies, NNTs for
protocol-deﬁned responder rate for brexpiprazole 2 mg and 4 mg
Table 3
Change from baseline to week 6 in PANSS total score by tertiles of duration of illness for the combined Phase 3 studies (efﬁcacy population).
Duration of illnessa Change from baseline to week 6 in PANSS total score
Placebo Brexpiprazole
2 mg 4 mg 2 mg + 4 mg
≤ 7 years, n 67 89 85 174
LS mean change (SE)b −13.39 (2.08) −20.74 (1.90) −19.44 (1.92) −20.12 (1.35)
Treatment difference (95% CI) – −7.35 (−12.9,−1.80) −6.05 (−11.6,−0.46) −6.71 (−11.6,−1.83)
p-value – 0.0097 0.0341 0.0073
N 7 and ≤ 16 years, n 77 80 84 164
LS mean change (SE)b −13.01 (1.91) −18.50 (1.92) −20.83 (1.86) −19.71 (1.34)
Treatment difference (95% CI) – −5.49 (−10.8,−0.15) −7.81 (−13.1,−2.56) −6.69 (−11.3,−2.10)
p-value – 0.0438 0.0037 0.0044
N 16 years, n 83 84 80 164
LS mean change (SE)b −12.52 (1.79) −16.12 (1.80) −19.69 (1.79) −17.92 (1.27)
Treatment difference (95% CI) – −3.60 (−8.60, 1.40) −7.16 (−12.1,−2.18) −5.43 (−9.76,−1.10)
p-value – 0.1577 0.0050 0.0142
Bold text indicates p b 0.05 compared with placebo.
CI, conﬁdence interval; LS, least squares; SE, standard error.
a Deﬁned by tertiles.
b LS mean (SE) change from baseline at week 6; p-value is derived from a mixed-model repeated measures analysis.
91C.U. Correll et al. / Schizophrenia Research 174 (2016) 82–92were 9 and 6–7, respectively; these values are in the same range as the
reported NNT values for olanzapine (NNT = 7) and risperidone
(NNT = 8) and numerically better than those for aripiprazole
(NNT = 10) and quetiapine (NNT = 10) (Leucht et al., 2013a). Simi-
larly, effect sizes were within the range of those reported for other anti-
psychotics (Leucht et al., 2013a). The ﬁnding that combined effect sizes
for the change in PANSS total scoreswere in the lower range of those re-
ported in the recent network meta-analysis (Leucht et al., 2013a) is in-
ﬂuenced by the fact that the combined placebo response across the two
brexpiprazole studies was relatively high, yet in one of the two studies
(Correll et al., 2015), the effect size (0.4) was in the mid-range of the
ranking in the network meta-analysis.
One limitation of the current analyses is the absence of an active
comparator in the Phase 3 trials. However, this meta-analysis indicates
that brexpiprazole 2 mg and 4 mg are effective for the treatment of
adults with acute exacerbation of schizophrenia, as evidenced by results
obtained from two Phase 3 placebo-controlled studies.
Additional long-term and real-world clinical data will be important
to fully evaluate the value of brexpiprazole for treating patients with
schizophrenia. While the lower, ineffective brexpiprazole dose range
of 0.25–1 mg has been clariﬁed in schizophrenia, as mentioned above,
titration and the upper dose range should be explored further. Efﬁcacy
data cannot be judged in isolation so it is important that pooled safety
data from the short-term studies and two open-label long-term studies
have indicated that brexpiprazole iswell tolerated in adultswith schizo-
phrenia (Kane et al, 2016-in press).
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